Premalignant manifestations of photoaging: Actinic keratoses and atypical nevi

Photodamaged Skin

Volumn , Issue , 2004, Pages 1-17

  Spencer, James M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895396538     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (35)

1. Nelson MA, Einspahr JG, Alberts DS. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett 1994; 85:23-29.
2. Spencer JM, Kahn SM, Jiang W. Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Arch Dermatol 1995; 131:796-800.
3. Gupta AK, Cooper EA, Feldman SR. A survey of office visits for actinic keratoses as reported by NAMCS, 1990-1999. National Ambulatory Medical Care Survey. Cutis 2002; 70(2 supp1):8-13.
4. Jeffes EW, Tang EH. Actinic keratosis. Current treatment options. Am J Clin Dermatol 2001; 1:167-179.
5. Ackerman AB. Opposing views of two academies about the nature of solar keratosis. Cutis 2003; 71:391-395.
6. Marks R, Foley C, Goodman G. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 1986; 115:649.
7. Mittelbronn MA, Mullins DL, Ramos-Caro FA, et al. Frequency of preexisting actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol 1998; 37:677-681.
8. Hurwitz RM, Monger LE. Solar keratoses: evolving squamous cell carcinoma, benign or malignant?. Dermatol Surg 1995; 21:184.
9. Brand D, Ackerman AB. Squamous cell carcinoma, not basal cell carcinoma, is the most common cancer in humans. J Am Acad Dermatol 2000; 42:523-526.
10. Lubritz RR, Smolewski SA. Cryosurgery cure rate of actinic keratoses. JAm Acad Dermatol 1982; 7:631-632.
11. Weinstock MA, Bingham SF, Cole GW. Reliability of counting actinic keratoses before and after brief consensus discussion: the VA Topical Tretinoin Chemoprevention (VATIC) trial. Arch Dermatol 2001; 137:1055-1058.
12. Bercovitch L. Topical chemotherapy of actinic keratoses of the upper extremity with tretinoin and 5-fluorouracil: a double blind controlled study. Br J Dermatol 1987; 116:549-552.
13. Kurwa HA, Barlow RJ. The role of photodynamic therapy in dermatology. Clin Exp Dermatol 1999; 24:143-148.
14. Weiss J, Menter A, Hevia O. Effective treatment of actinic keratoses with 0.5% fluorouracil cream for I, 2, or 4 weeks. Cutis 2002; 70(suppl 2):4-7.
15. Stockfleth E, Meyer T, Benninghoff B. Successful treatment of actinic keratosis with imiquimod cream 5%; a report of 6 cases. Br J Dermatol 2001; 144:1050-1053.
16. Stockfleth E, Meyer T, Benninghoff B. A randomize. double blind, vehicle controlled study to assess 5% imiquimod cream for the treatment of multiple aClinic keratoses. Arch Dermatol 220; 138:1498-1502.
17. Wolf JE, TAylor JR, Tschen E, et al. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40:709-713.
18. Rivers JK, Arlette J, Shear N. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146:94- 100.
19. McEwan LE, Smith JG. Topical diclofenaclhyaluronic acid gel in the treatment of solar keratoses. Aust J Dermatol 1997; 38:187-189.
20. Piacquadio DJ, Chen DM, Farber HF, Fowler JF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp. Arch Dermatol 2004; 140:41-46.
21. Smith S, Piacquadio D, Morhenn V, Atkin D, et al. J Drugs Dermatol. 2003; 2(6):629-635.
22. Thorne EG. Long-term clinical experience with a topical retinoid. Br J Delmatol 1993; 127(suppl):31-36.
23. Geller AC, Miller DR, Annas GD. Melanoma incidence and mortality amona US whites 1969-1999. JAMA 2002; 288:1719-1720.
24. Green A, Swerdlow AJ. Epidemiology of melanocytic nevi. Epidemiol Rev 1989; 11:204-221.
25. Green A, Siskind Y, Hansen ME. Melanocytic nevi in school children in Queensland. JAm Acad Dermatol 1989; 20:1054-1060.
26. Gallagher RP, Mclean DI, Yang CPO Suntan, sunburn, and pigmentation factors and the frequency of acquired melanoncytic nevi in children. Arch Dermatol 1990; 126:770-776.
27. Kelly JW, Rivers JK, MacLennan R. Sunlight: a major factor associated with the development of melanocytic nevi in Australian school children. J Am Acad Dermatol 1994; 30:40-48.
28. Gruber SB, Barnhill RN, Stenn KS. Nevomelanocytic proliferations in association with cutaneous malignant melanoma: a multivariate analysis. J Am Acad Dermatol 1989; 21(4):773-780.
29. Norris W. A case of fungoid disease. Edinburgh Med Surg J. 1820; 16:562-565.
30. Clark WH, Reamer RR, Greene M, et al. Origin of the familial malignant melanomas from heritable melanocytic lesions. “The B-K mole syndrome.” Arch Dermatol 1978; 114:732-738.
31. Sander C, Tschochohei H, Hagedorn M. Epidemiology of dysplastic nevus. (German) Hautarzt 1989; 40:758-760.
32. Augustsson A, Stierner U, Suurkula M, et al. Prevalence of common and dysplastic naevi in a Swedish population. Br J Dermatol 1991; 124:152-156.
33. Duncan LM, Berwick M, Bruijn JA. Histopathologic recognition and grading of dysplastic melanocytic nevi: an intraobserver agreement study. J Invest Dermatol 1993; 100(3):318S-321S.
34. Halpern AC. Precursor melanocytic lesions. In: Miller SJ, Maloney ME, Eds. Cutaneous Oncology. Oxford. UK: Blackwell Science, 1998.
35. Tripp JM, Kopf AW, Marghoob AA. Management of dysplastic nevi: a survey of fellows of the American Academy of Dermatology. J Am Acad Dermatol 2002; 46(5):674-682.